Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548532 | 0.81 | LMNA (0.34) | TSHRGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL3190483 | 0.81 | GRIN1 (0.48) | TSHRGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL733849 | 0.81 | GRIN1 (0.48) | TSHRGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL18028703 | 0.81 | LMNA (0.34) | TSHRGRIN1GRIN2AGRIN2DGRIN3B | |
| Bromide SCHEMBL4732099 | 0.78 | GRIN1 (0.46) | TSHRGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL4055257 | 0.78 | ALDH1A1 (0.31) | LMNAALDH1A1MAPTHPGDMPI | |
| SCHEMBL4058299 | 0.78 | GRIN1 (0.39) | TSHRGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL3382980 | 0.77 | GRIN1 (0.46) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL732916 | 0.77 | GRIN1 (0.52) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Methyl Alcohol SCHEMBL28225130 | 0.76 | TSHR (0.48) | TSHRGRIN1GRIN2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116046926-B | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-116046926-A | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-102947283-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-02-27 | — | — | CN | claimed |
| EP-1999100-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-12-10 | — | — | EP | claimed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| CN-116046926-B | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4209494-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-116046926-A | Detection method of 1-bromo-3, 5-dimethyl adamantane related substances | 合肥久诺医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-113125574-A | Method for separating and measuring related substances of memantine starting material by gas chromatography | 北京万全德众医药生物技术有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1789380-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | Justus-Liebig-Universität Giessen (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010362-A1 | AMINO ADAMANTANE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-5599998-A | DEHALOGENATION WITH LITHIUM FORMING THE CHEMICAL INTERMEDIATES | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | TNF, GCDH, LITAF | TSHR 4444/4885GRIN1 90/4885GRIN2A 198/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | TSHR 2589/4885GRIN1 2471/4885GRIN2A 3198/4885 |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | VIP, PREP, PRAP1 | TSHR 3278/4885GRIN1 2335/4885GRIN2A 3362/4885 |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | PNMT, PSEN2, CHRNA5 | TSHR 3555/4885GRIN1 83/4885GRIN2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.